INTROduCTION
In an adult human, 50-100 mmol of H + are generated every day. Main sources of acids include the metabolism of aminoacids such as cystine, cysteine, methionine, lysine, arginine, the metabolism of phospholipids, glucose and fatty acids. The role of kidney in maintaining normal acid-base balance may be divided into two main processes: 1) reabsorption of filtered HCO 3 -, which takes place fundamentally in the proximal tubule, and 2) excretion of net protons (H + ) as titratable acid and ammonium, which occurs in the distal nephron (Fry & Karet, 2007; Ring et al., 2005) .
Reabsorption of bicarbonate can increase in the presence of hypovolaemia (due to the action of angiotensin II), hypokalemia, acidosis, hypercapnia, hyperaldosteronism. Conversely, hypervolaemia, hyperkalemia, alkalosis, hypoaldosteronism, and also increased PTH level, decrease the reabsorption of bicarbonate.
Interestingly, the food contents can play a role in bicarbonate amount in the body. It is assumed that sources of potassium in food (predominantly plants) are, in general, potential sources of bicarbonate (Demigne, 2004) .
Proximal tubule HCO 3 -reabsorption
Eighty to ninety percent of freely filtered HCO 3 -is reabsorbed in the proximal tubule. In the lumen, filtered HCO3 -reacts with H + to form carbonic acid, which, in the presence of membrane-bound carbonic anhydrase (CAIV) promptly dissociates into CO 2 and water. CO 2 freely diffuses into the proximal tubular cells where it is combined with water to produce intracellular H + and HCO 3 -in the presence of cytoplasmic carbonic anhydrase II (CAII). HCO 3 -is cotransported with Na + into blood via NBC-1. The intracellular H + produced by CAII is secreted into the lumen mainly via the Na + -H + exchanger (NHE-3) located on the luminal membrane. Proximal tubular cells are also able to generate bicarbonate and ammonia through the deamination of glutamine to glutamate (Laing et al., 2005) .
The mechanisms of proximal tubule bicarbonate reabsorption are presented in Fig. 1 (from Pereira et al., 2009 ).
distal tubule and collecting duct acid secretion
In the distal nephron three processes may contribute to urinary acidification: 1) reclamation of 10-20% of filtered HCO 3 -that is not reabsorbed by proximal tubules, 2) titration of divalent basic phosphate (HPO 4 2-) which is converted to the monovalent acid form (H 2 PO 4 -)
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The acidification process in α-intercalated cells of the distal nephron is shown in Fig. 2 (from Pereira et al., 2009) .
dIAgNOSTIC APPROACH
Clinical and functional studies allow classification of RTA into four types, numbered in the order of discovery: proximal RTA (type 2), distal RTA (type 1), hyperkalemic distal RTA (type 4) and combined proximal and distal RTA (type 3).
All types of RTA can be characterized by the metabolic acidosis with the presence of a normal anion gap and subsequently, hyperchloremia. The patient should not present gastrointestinal HCO 3 -losses and not be taking drugs such as acetazolamide. The next step requires the evaluation of urine anion gap (UAG). UAG (Na + + K + -Cl -) provides estimation of urinary ammonium secretion. In physiological conditions, UAG is positive due to the presence of small amounts of unmeasured anions (sulfates, phosphates). In metabolic acidosis any increase in NH4 + excretion is accompanied by a parallel increase in Cl -, thus UAG is more negative. Apart from patients with proximal RTA, the others present with positive UAG.
In a patient with a negative UAG the definite diagnosis of proximal RTA is established with a high (>15%) urine HCO 3 -excretion at normal plasma HCO 3 -concentration.
In a patient with a positive UAG measuring of plasma K + concentration would be the next step in the diagnosis. In case of normal or lower K + values, the inability to lower the urine pH below 5.5 after NH 4 Cl load or furosemide administration establishes the diagnosis of distal RTA. When the value of plasma K + is increased, the finding of urine pH higher than 5.5 after NH 4 Cl load will identify patients with hyperkalemic distal RTA caused by a 'voltage-dependent' defect. When the urine pH is lower than 5.5, the diagnosis of hyperkalemic RTA (type 4) is confirmed. The presence of a moderate degree of HCO 3 -wasting (5 to 15% of fractional HCO 3 -excretion at normal plasma HCO 3 -) indicates type 3 RTA .
The diagnostic work-up in a patient with the suspicion of RTA is presented in Fig. 3 (from Soriano, 2002) .
gENETIC CAuSES OF RTAS
In recent years remarkable progress has been made in the unraveling of the molecular pathogenesis of hereditary diseases caused by mutations in genes encoding transporters in renal tubule.
Inherited forms of distal RTA
The inherited forms of distal RTA include three variants: autosomal dominant and autosomal recessive with or without deafness (Karet, 2002) .
Autosomal dominant distal RTA has been found to be associated with mutations in the SLC4A1 gene encoding Cl -HCO 3 -exchanger AE1. AE1, an integral membrane glycoprotein, is predominantly expressed in erythrocytes (eAE1) and in the kidney (kAE1). Because of the expression of AE1 in two different cell types (red blood cells and distal tubular cells), SLC4A1 mutations can result in two different phenotypes: hereditary spherocytosis (or, in general, erythrocyte abnormalities) and distal RTA (Pereira et al., 2009) . The majority of SLC4A1 mutations cause only erythrocyte abnormalities without renal disorders. A plausible explanation is that the remaining function of the exchanger in heterozygotes may be insufficient to preserve the integrity and function of erythrocytes but sufficient to maintain normal distal H + secretion. On the other hand, distal-RTA SLC4A1 mutations are rarely accompanied by erythrocyte abnormalities. The answer to this phenomenon is probably in the segregation of the mutations; in spherocytosis the mutations are distributed throughout AE1 cytoplasmic and transmembrane domains, whereas distal-RTA mutations are restricted to the AE1's transmembrane domain (Alper, 2002) .
Autosomal recessive distal RTA with deafness is related to mutations in the proton pump. The gene involved (ATP6V1B1) encodes the B1 subunit of H + -ATPase in α-intercalated cells (Borthwick et al., 2002) . Mutations lead to the disruption of the structure or abrogation of the production of normal B1 subunit protein. H + -ATPase in human cochlea is necessary to maintain normal endolymph pH. Clinically, there is large variability of deafness severeness with different progression.
Autosomal recessive distal RTA with preserved hearing is a consequence of defective gene ATP6V0A4 which encodes a kidney-specific a4 isoform subunit of H + -ATPase. It seems that the a4 subunit is essential for proton pump function in the kidney (Smith et al., 2000) .
Inherited forms of proximal RTA
The proximal RTA resulting from Fanconi syndrome is frequently part of a systemic syndrome. The inheritance pattern is usually autosomal recessive and the diseases are: cystinosis, tyrosinaemia, galactosaemia, Fanconi-Bickel syndrome and others.
Primary isolated proximal RTA is a rare disorder (Gross et al., 2008) . It can be divided into three categories: 1) autosomal recessive with ocular abnormalities, 2) autosomal dominant 3) sporadic (Igarashi et al., 2002) .
Autosomal recessive proximal RTA is a rare disorder with severe growth retardation and ocular abnormalities such as glaucoma, cataracts and band keratopathy which may progress with age. Intellectual impairment and enamel defects of teeth are common. The disorder is caused by mutations of the gene encoding the sodium bicarbonate transporter NBC1 (SLC4A4) (Dinour et al., 2004) . In consequence, reduced activity of the transporter and/or defects in intracellular trafficking are present. Ocular tissues have also been shown to express NBC1 which can explain the development of ocular abnormalities. NBC1 is also expressed in the pancreas, and some patients with these mutations demonstrate abnormal pancreatic function.
Another inherited form of proximal RTA is the one resulting from mutations in the gene that encodes CAII. CAII is localized in proximal tubular cells and in α-intercalated cells of the cortical and outer medullary collecting tubules. That is why this type of RTA presents with some proximal and distal components (RTA type 3). Clinically, patients present with osteopetrosis, cerebral calcification and mental retardation.
Autosomal dominant proximal RTA was first described in a Costa Rican family, patients presented with growth retardation and osteomalacia. Recently, Katzir et al. (2008) described a second family. However, the gene associated with this clinical presentation has not been identified yet.
Recent evidence suggests that a strong candidate for proximal RTA is the TASK gene. TASK2-potassium channel seems to be important in bicarbonate reabsorption in renal proximal tubules. Studies on TASK2 gene knock-out mice showed metabolic acidosis with low bicarbonate levels (Warth et al., 2004) .
Inherited forms of type 4 RTA
Type 4 RTA is a heterogenous group of disorders associated with hyperkalemia due to aldosterone deficiency or disorders in aldosterone molecular signaling.
Hyperkalemic RTA of hereditary origin is most frequently observed in children with primary pseudohypoaldosteronism type 1 (PHA1). It can have autosomal dominant or recessive form (Hanukoglu, 1991) . The autosomal dominant one is a mild kidney disorder without any other organ involvement and is associated with mutation (loss-of-function type) in the mineralocorticoid receptor gene (MRL gene). The autosomal recessive PHA1 is related to sodium transport defects not only in the kidney, but also in other aldosterone-target organs, such as colon, lungs or salivary glands. The symptoms are more pronounced.
Pseudohypoaldosteronism type 2 (PHA2) or Gordon's syndrome, is another inherited cause of type 4 RTA (autosomal dominant pattern). Clinical presentation includes hyperkalemia with hypertension and low or normal levels of plasma aldosterone. The basic abnormality is due to gain-of-function mutations in the gene of two isoforms of WNK serine-threonine kinases, WNK4 and WNK1 genes (Wilson et al., 2001) . WNK4 is found in the distal nephron and regulates sodium and chloride reuptake and inhibits potassium efflux.
Aquired causes of RTAs
Aquired forms of RTA can develop quite commonly (Soriano, 2002) . Main causes of secondary RTA are presented in Table 1 .
Recently, topiramate, a drug used in the therapy of epilepsy, has been shown to induce RTA. The mechanism involves the inhibition of carbonic anhydrases II and IV (Mirza et al., 2009) .
RTA after kidney transplantation
RTA observed in patients after kidney transplantation is usually asymptomatic and subclinical. It may affect even up to 40% of transplanted subjects (Malik et al., 2011) . Many different factors have been suggested to be associated with post-transplant RTA: ischemic damage, acute tubular necrosis, graft rejection, the use of calcineurin inhibitors (cyclosporine, tacrolimus). Therefore, RTA that occurs early following kidney transplantation is predominantly a consequence of acute renal failure and disappears quickly (Heering et al., 1996) . On the other hand, RTA found in late post-transplant period is usually a result of chronic graft rejection or calcineurin inhibitors (CNI) nephrotoxicity. Kidney graft interstitial inflammation or obstructive nephropathy may play a role in the development of RTA. It has also been suggested that alloantigens trigger a direct immune-mediated mechanism by means of specific interference with molecules taking part in tubular acid handling (Ambuhl et al., 2007) . Patients with secondary hyperparathyroidism before transplantation tend to develop post-transplant RTA as PTH causes bicarbonate to leak from proximal tubules.
The use of corticosteroids and CNIs may lead to a defect of ammonia synthesis in the proximal tubule due and others to insulin resistance, and in consequence to metabolic acidosis.
There are, however, other mechanisms of RTA development during cyclosporine use in renal transplant recipients. The mechanism of action of CNIs involves the reaction between calcineurin-inhibitory complex and cytosolic receptor, cyclophilin A. Cyclosporin also inhibits the peptidyl prolyl cis-trans isomerase (PPIase) activity on cyclophilin A (Watanabe et al., 2005) . PPIase of cyclophilins is also present in intercalated cortical collecting duct cells and may be inhibited by cyclosporin. In this indirect way the hensin polymerization necessary in transforming intercalated cells from β-type (bicarbonate secretion) to α-type (acid secretion) is also inhibited. Chronic CNI nephrotoxicity leads to interstitial histological damage of the kidney.
Classic distal RTA has been described as the main form of RTA in subjects after kidney transplantation. However, type 4 may also be seen in subjects with diabetes mellitus using angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) (Schwarz et al., 2006) .
TREATmENT
The aim of RTA treatment is not only to correct the biochemical abnormalities, but also to improve the growth of children and to prevent the development of nephrocalcinosis and chronic kidney disease. The basis of therapy is to administer continually appropriate amounts of alkali in the form of bicarbonate or citrate (Soriano, 2002) .
For distal RTA, the amount of administered alkali should be 1-2 mmol/kg/day. However, even more important is the proper supplementation of potassium, as the correction of acidosis can enhance hypokalemia. The preferred form of potassium administration is potassium citrate because of its alkalizing effect and protection against hypocitraturia.
For proximal RTA, the amount of administered alkali is very large (5-15 mmol/kg/day). Administration of potassium salts is advised.
For hyperkaemic RTA, the treatment depends on the underlying cause. Potassium-retaining drugs should always be avoided. Fludrocortisone therapy may be useful in hyporeninemic hypoaldosteronism, preferably in combination with a loop diuretic.
CONCludINg REmARKS
There are more and more molecular developments concerning mutations in genes encoding transporters or channel proteins in renal tubules that may result in primary RTA. New clinical entities (e.g., kidney transplantation) broaden the spectrum of acquired forms of RTAs. Further studies improving our knowledge on RTA pathophysiology and providing a basis of targeted therapeutic interventions are awaited.
